AU2004210975B2 - Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers - Google Patents

Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers Download PDF

Info

Publication number
AU2004210975B2
AU2004210975B2 AU2004210975A AU2004210975A AU2004210975B2 AU 2004210975 B2 AU2004210975 B2 AU 2004210975B2 AU 2004210975 A AU2004210975 A AU 2004210975A AU 2004210975 A AU2004210975 A AU 2004210975A AU 2004210975 B2 AU2004210975 B2 AU 2004210975B2
Authority
AU
Australia
Prior art keywords
protein
antibody
cell
cancer
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004210975A
Other languages
English (en)
Other versions
AU2004210975A1 (en
Inventor
Pia M. Challita-Eid
Mary Faris
Wangmao Ge
Jean Gudas
Aya Jakobovits
Steven B. Kanner
Karen Jane Meyrick Morrison
Robert Kendall Morrison
Juan J. Perez-Villar
Arthur B. Raitano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of AU2004210975A1 publication Critical patent/AU2004210975A1/en
Application granted granted Critical
Publication of AU2004210975B2 publication Critical patent/AU2004210975B2/en
Priority to AU2008203053A priority Critical patent/AU2008203053B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004210975A 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers Expired AU2004210975B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008203053A AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44663303P 2003-02-10 2003-02-10
US60/446,633 2003-02-10
PCT/US2004/003984 WO2004072263A2 (en) 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008203053A Division AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Publications (2)

Publication Number Publication Date
AU2004210975A1 AU2004210975A1 (en) 2004-08-26
AU2004210975B2 true AU2004210975B2 (en) 2008-04-10

Family

ID=32869540

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2004210975A Expired AU2004210975B2 (en) 2003-02-10 2004-02-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2008203053A Expired AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2010201615A Expired AU2010201615B2 (en) 2003-02-10 2010-04-22 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2008203053A Expired AU2008203053B2 (en) 2003-02-10 2008-07-10 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2010201615A Expired AU2010201615B2 (en) 2003-02-10 2010-04-22 Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers

Country Status (6)

Country Link
EP (2) EP1594892A2 (https=)
JP (3) JP2007524361A (https=)
AU (3) AU2004210975B2 (https=)
CA (2) CA2515699C (https=)
IL (1) IL170080A (https=)
WO (1) WO2004072263A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501741D0 (en) * 2005-01-27 2005-03-02 Binding Site The Ltd Antibody
EP1840133A1 (en) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. New immunomodulating oligopeptides
US7718629B2 (en) * 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
JP2013179911A (ja) * 2012-03-02 2013-09-12 Dainippon Printing Co Ltd 電極付き細胞試験具の接続装置、及びそれを用いた細胞試験装置
EP3494996B1 (en) * 2012-08-23 2026-04-15 Agensys, Inc. Antibody drug conjugates (adc) that bind to 158p1d7 proteins
JP7341060B2 (ja) * 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
WO2023105976A1 (ja) * 2021-12-08 2023-06-15 富士フイルム株式会社 臨床試験支援装置、臨床試験支援装置の作動方法、および臨床試験支援装置の作動プログラム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016593A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0462145B1 (en) 1989-03-07 1994-04-27 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
ATE157012T1 (de) 1989-11-03 1997-09-15 Univ Vanderbilt Verfahren zur in vivo-verabreichung von funktionsfähigen fremden genen
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ES2264239T3 (es) 1990-06-27 2006-12-16 Princeton University Complejo de proteinas p53/p90'.
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
CN1127527A (zh) 1993-05-17 1996-07-24 加利福尼亚大学董事会 人免疫缺陷型病毒感染和艾滋病的核酶基因治疗方法
US5837501A (en) 1993-07-09 1998-11-17 Akzo Nobel N.V. Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1996002561A1 (en) 1994-07-20 1996-02-01 The General Hospital Corporation Interaction trap systems for detecting protein interactions
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
JP2001504799A (ja) 1996-03-11 2001-04-10 エピミューン インコーポレイテッド Ｈｌａ分子への結合アフィニティーが増加したペプチド
CA2252886C (en) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Three-hybrid screening assay
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
ES2290964T3 (es) 1996-10-15 2008-02-16 The Regents Of The University Of California Modelos animales de la evolucion del cancer de prostata humano.
US6365797B1 (en) 1997-10-15 2002-04-02 The Regents Of The University Of California Mice models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
US5840501A (en) 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
WO2001081363A1 (en) * 2000-04-27 2001-11-01 Smithkline Beecham Corporation Novel compounds
WO2002026826A2 (en) * 2000-09-27 2002-04-04 Curagen Corporation Proteins and nucleic acids encoding same
EP1576146A2 (en) * 2002-06-03 2005-09-21 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN104010774B (zh) 2011-09-15 2017-10-13 康富真信息技术股份有限公司 用于自动生成机器人程序的系统和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016593A2 (en) * 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2002020569A2 (en) * 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
WO2002059377A2 (en) * 2001-01-24 2002-08-01 Protein Design Labs Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer

Also Published As

Publication number Publication date
AU2010201615B2 (en) 2012-08-16
EP2343315A2 (en) 2011-07-13
AU2008203053B2 (en) 2010-02-18
CA2515699C (en) 2015-01-27
JP2007524361A (ja) 2007-08-30
WO2004072263A2 (en) 2004-08-26
CA2860151A1 (en) 2004-08-26
WO2004072263A3 (en) 2004-12-23
AU2010201615A1 (en) 2010-05-13
AU2004210975A1 (en) 2004-08-26
JP2011200233A (ja) 2011-10-13
AU2008203053A1 (en) 2008-07-31
EP1594892A2 (en) 2005-11-16
EP2343315A3 (en) 2011-11-23
CA2515699A1 (en) 2004-08-26
IL170080A (en) 2015-03-31
JP2015057068A (ja) 2015-03-26

Similar Documents

Publication Publication Date Title
AU2002361610B2 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7250498B2 (en) Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
US8951744B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2002361610A1 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2010226920A1 (en) Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US6863892B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2004235755A1 (en) Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer
AU2010201615B2 (en) Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
AU2007201445A1 (en) Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
CA2514058A1 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US7811575B2 (en) Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
CA2588564A1 (en) Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer
CA2496566A1 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
AU2007216892B2 (en) Nucleic acids and corresponding proteins entitled 273P4B7 useful in treatment and detection of cancer
AU2002258688A1 (en) Nucleic acid and corresponding protein entitled 238p1b2 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN EXTENDED TO 25 SEP 2004.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired